Previous:T-MAXIMUM Biotech's universal cell products were showcased at the 2023ASCO Annual Meeting
Next:T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma
